Home » Agendia Obtains European Rights to Arcturus TUO-gene Profile
Agendia Obtains European Rights to Arcturus TUO-gene Profile
Agendia and Arcturus have signed a license agreement under which Agendia obtained the exclusive European rights to the TUO-gene expression profile (Tumor of Unknown Origin) discovered by Arcturus. Using this profile, Agendia has developed CupPrint, a gene expression-based diagnostic test to be used with patients diagnosed with Cancer Unknown Primary. Financial details of the agreement were not disclosed.
ArriveNet
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May